Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity
The DOI matches its Crossref record; 171 of the 171 references it cites were found in a registry or an index.
Abstract
The development of glucagon-like peptide 1 receptor agonists (GLP-1RA) for type 2 diabetes and obesity was followed by data establishing the cardiorenal benefits of GLP-1RA in select patient populations. In ongoing trials investigators are interrogating the efficacy of these agents for new indications, including metabolic liver disease, peripheral artery disease, Parkinson disease, and Alzheimer disease. The success of GLP-1–based medicines has spurred the development of new molecular entities and combinations with unique pharmacokinetic and pharmacodynamic profiles, exemplified by tirzepatide, a GIP-GLP-1 receptor coagonist. Simultaneously, investigational molecules such as maritide block the GIP and activate the GLP-1 receptor, whereas retatrutide and survodutide enable simultaneous activation of the glucagon and GLP-1 receptors. Here I highlight evidence establishing the efficacy of GLP-1–based medicines, while discussing data that inform safety, focusing on muscle strength, bone density and fractures, exercise capacity, gastrointestinal motility, retained gastric contents and anesthesia, pancreatic and biliary tract disorders, and the risk of cancer. Rapid progress in development of highly efficacious GLP-1 medicines, and anticipated differentiation of newer agents in subsets of metabolic disorders, will provide greater opportunities for use of personalized medicine approaches to improve the health of people living with cardiometabolic disorders.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Concerns regarding pancreatitis have not been substantiated in large cardiovascular outcome trials (92, 93).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [92]
In the citing paper
“These symptoms frequently manifest during the initial treatment phase, affecting approximately 50% to 60% of patients [8], but they generally diminish over time, with their occurrence being dose-dependent.”
From Exploring the Side Effects of GLP-1 Receptor Agonist: To Ensure Its Optimal Positioning (2025) · cites this paper as [8]
In the citing paper
“These symptoms frequently manifest during the initial treatment phase, affecting approximately 50% to 60% of patients [8], but they generally diminish over time, with their occurrence being dose-dependent.”
From Exploring the Side Effects of GLP-1 Receptor Agonist: To Ensure Its Optimal Positioning (2025) · cites this paper as [8]
In the citing paper
“These symptoms frequently manifest during the initial treatment phase, affecting approximately 50% to 60% of patients [8], but they generally diminish over time, with their occurrence being dose-dependent.”
From Exploring the Side Effects of GLP-1 Receptor Agonist: To Ensure Its Optimal Positioning (2025) · cites this paper as [8]
In the citing paper
“Furthermore, long-term therapy is associated with nutritional deficiencies, lean mass loss, and frequent GI adverse events, including nausea, vomiting, diarrhea, and constipation, which may affect up to 70-85% of patients and lead to treatment discontinuation [22,38,41,60,61]”
From Nutritional Approaches to Enhance GLP-1 Analogue Therapy in Obesity: A Narrative Review (2025) · cites this paper as [41]
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Self-citationTirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236
Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index
MAGIC, Speliotes, E. K., on behalf of Procardis Consortium, Willer, C. J., Berndt, S. I., Monda, K. L., Thorleifsson, G., Jackson, A. U., Allen, H. L., Lindgren, C. M., et al. (2010) · Nature Genetics · doi:10.1038/ng.686 · Cited by 2,912
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Armstrong, M. J., Gaunt, P., Aithal, G. P., Barton, D., Hull, D., Parker, R., Hazlehurst, J. M., Guo, K., Abouda, G., Aldersley, M. A., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00803-x · Cited by 2,203
Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
Drucker, D. J. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.001 · Cited by 2,170
Self-citationEffects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
Perkovic, V., Tuttle, K. R., Rossing, P., Mahaffey, K. W., Mann, J. F. E., Bakris, G., Baeres, F. M. M., Idorn, T., Bosch-Traberg, H., Lausvig, N. L., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2403347 · Cited by 2,099
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096
Research works printed but not linked: 1
- Styrkarsdottir, Obesity variants in the GIPR gene do not associate with risk of fracture or bone mineral density, J Clin Endocrinol Metab
Cited by
Items 301–381 of 381
Shimada, H., Fukasawa, T., Mizuno, K., Okazawa, Y., Yokogawa, K., & Kawakami, K. (2026) · Diabetes & Metabolism · doi:10.1016/j.diabet.2026.101760
Geriatric Pharmacotherapy Case Series: GLP-1 RA for Weight Management in Older Adults
Toma, L., Buckley, K. D., & Early, N. K. (2026) · The Senior Care Pharmacist · doi:10.4140/tcp.n.2026.78
Liu, D., Dou, C., Ye, C., Chen, M., Kong, L., Zhu, Z. G., Zheng, J., Xu, M., Xu, Y., Li, M., et al. (2026) · Life Medicine · doi:10.1093/lifemedi/lnag015 · Cited by 1
Fasinu, P. S., & Wilborn, T. W. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-44037-3.00655-2
Hong, K. M., SULO, S. S., Wang, W., Kim, M., Hong, L., Kerr, K. W., Fan, L., & Williams, D. (2026) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s574765 · Cited by 1
Davies, M., & Härmark, L. (2026) · Drug Safety · doi:10.1007/s40264-026-01676-4
“Less is also known regarding use of these products amongst children and adolescents, those hospitalized with severe illness, and the elderly [9].”
InfluentialLiu, D., Wang, L., Zhu, L., Wang, Y., & Pei, L. (2026) · Joint Bone Spine · doi:10.1016/j.jbspin.2026.106072
Endoluminal device induces insulin sensitivity and greater weight control than semaglutide in pigs
Russo, S. L. M. L., Neto, M. G., Previti, E., Bove, V., Mingrone, G., & Boškoski, I. (2026) · Gut · doi:10.1136/gutjnl-2025-337077
Meftah, A., Yoade, B., Cowart, C., Choi, A., Popoola, O., Afe, O., Efremoff, S., Ezema, C., Johnson, B. O., Lawrence, J., et al. (2026) · Cureus · doi:10.7759/cureus.109089
“It was first approved as Ozempic for diabetes in 2017, and later as Wegovy for obesity in 2021, based on STEP trials showing 15-20% weight loss [11,48].”
Taiwanese consensus statement on the use of diabetes‐specific formula: Scientific evidence
Ch, C., Peng, H.-Y., Lee, C., Wang, C., Ko, Y., Chen, W., Hsu, P.-H., Huang, C., Yang, Y., Yeh, K.-M., et al. (2026) · Journal of Diabetes Investigation · doi:10.1111/jdi.70329
“For example, GLP-1 receptor agonists (GLP-1 RAs), primarily used for glycemic control in patients with T2D and also for weight management, may cause muscle loss and gastrointestinal side effects, leading to impaired nutrient absorption 38, 39 .”
The role of bariatric metabolic endoscopy in 2026 and beyond
Norton, B. C., Ranganath, S., Bhandari, M., & Haidry, R. J. (2026) · Frontline Gastroenterology · doi:10.1136/flgastro-2025-103561
The effects of Hangzhou white tea on lowering lipids and blood glucose in mice
Yu, H., Huang, H., Zhao, Y., Cui, H., Cheng, Z., & He, P. (2026) · CyTA - Journal of Food · doi:10.1080/19476337.2026.2662054
McGuane, C., Farhadhar, N., Sharieff, K. A., Petrosky, S. N., & Alabasi, K. (2026) · Cureus · doi:10.7759/cureus.109731 · Cited by 1
Le, D., Kilpatrick, M., Kraft, W. K., Grams, M. E., Jaar, B. G., & Shin, J.-I. (2026) · Kidney International Reports · doi:10.1016/j.ekir.2026.106618
“33,44 GLP-1s were generally safe without increased risk of cholecystitis or pancreatitis.”
The GLP-1 Ceiling and GIP Dividend
Sun, Y., Lu, Y., & Wang, N. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2026.02.5136
Dietitians’ attitudes toward GLP-1s: weight bias and professional identity in an Israeli context
Cohen, B.-C., & Shabot, S. C. (2026) · Fat Studies · doi:10.1080/21604851.2026.2682774
“This reframing from their role providing sustained relational care intensifies the tensions in their professional identity (Drucker 2024).”
Choudhury, A., Kodra, J. D., Mathson, L., Hanley, J., LoGiudice, A. J., & Sullivan, C. W. (2026) · Hand · doi:10.1177/15589447261451445 · Cited by 1
Zarei, M., & Hajiani, Y. (2026) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-026-02196-y
“In parallel, both GLP-1RAs and dual incretin agonists have demonstrated clinically meaningful effects on body weight and cardiometabolic risk, thereby expanding the therapeutic landscape from glucose lowering toward multisystem metabolic disease management [1, 2].”
Efficacy of glucagon-like-peptide-1 agonists for weight loss in adults with CHD
Varghese, P., Elder, R. W., Vinocur, J. M., Spatz, E. S., Shabanova, V., McCollum, S., Harper, M., & Pastor, T. A. (2026) · Cardiology in the Young · doi:10.1017/s1047951126113109 · Cited by 1
McGonigle, J., Castro, M., Shilyaeva, Y., Thomas, D., & Edwards, M. (2026) · Journal of Diabetes Science and Technology · doi:10.1177/19322968261450596
Beig, J., Ta, J., Jones, S., Scott, E., Sofi, K., Osler, F., Jansen, M., & Chhabra, P. (2026) · Chronic Diseases and Translational Medicine · doi:10.1002/cdt3.70059 · Cited by 1
Patil, M., Piccinini, F., Johnstone, E. K. M., Casari, I., & Falasca, M. (2026) · Bioscience Reports · doi:10.1042/bsr20250114 · Cited by 1
Li, R., Zhao, X., Shen, J., Luo, B., Wang, Y., & Duan, Y. (2026) · Preventive Medicine Reports · doi:10.1016/j.pmedr.2026.103548
“Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have emerged as highly effective agents for glycemic control and weight reduction, with rapidly expanding indications in both T2DM and obesity management (Wong et al., 2025; Drucker, 2024).”
Ahmed, A., Aamir, A. H., Atiq, M., Hasan, M. I., Miyan, Z., Shafique, K., Shaheer, A., Zahir, M. A., & Hussain, A. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71034
“The findings also predate the expansion of real-world safety data on glucagon like peptide-1 receptor agonists for weight management [15, 16].”
Kiyosue, A., Sato, M., Cai, Z., Fukushima, Y., Takai, M., Takahashi, T., Nagashima, H., Suo, S., Takeda, R., Shimoura, K., et al. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03660-x · Cited by 1
“Currently available pharmacotherapies include glucagon-like peptide 1 (GLP-1) receptor agonists, which are used to treat diabetes and have been shown to reduce body weight [21].”
Laing, K. L., Levy, J. L., Wilkinson, M. J., Varshney, S., Panda, S., Taub, P. R., & Manoogian, E. N. C. (2026) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2026.1725278
Pan, S., Weng, C., Sheen, Y., Tsai, S.-F., Lin, J., Chen, J., Lin, C., Huang, S.-P., Chang, C.-J., Lin, H.-J., et al. (2026) · The American Journal of Medicine · doi:10.1016/j.amjmed.2026.06.023 · Cited by 1
Rebooting blood vessel repair: implications of the SEMA-VR CardioLink-15 trial
Verma, R., Verma, M., Park, B., Teoh, H., Quan, A., Connelly, K. A., & Hess, D. A. (2026) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000001323
Carmina, E., & Longo, R. A. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15135165 · Cited by 4
“These substances have several mechanisms of action, including reduction of gastric emptying, inhibition of glucagon secretion, beneficial changes in the intestinal microbiome, and direct effects on hypothalamic nuclei to enhance satiety (which promotes weight loss) [17,27].”
InfluentialChen, J., Liu, K.-W., Huang, Y., Meyerowitz‐Katz, G., Tsai, T., & Su, P. (2026) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188261460592 · Cited by 1
Lui, D. T. W., Zou, X., Lee, C., Chow, W.-S., Fong, C. H. Y., Cheung, M. C. Y. Y., Cheung, K. S., Ho, A. Y. Y., Yeung, B. Y. T. A., Wong, T.-W., et al. (2026) · Endocrine Practice · doi:10.1016/j.eprac.2026.06.012
Pendrey, A., Sierra, J. A. R., Lobo, F. A. A., Herrera, E. J. R., Muñoz, Y. M. F., & Sevilla‐Martir, J. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03702-4
“These actions lead to a long-term weight loss and improved glycemic control [14].”
InfluentialChan, T. C., Brennan, J. J., Killeen, J. P., & Castillo, E. M. (2026) · Emergency Care and Medicine · doi:10.3390/ecm3030022
“Other significant adverse events include metabolic and electrolyte derangements, including hypoglycemia and acute kidney injury [32].”
Li, J., Li, J., Xu, X., Wang, N., Lu, Y., & Wang, B. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-026-03304-y
“The remarkable clinical success of glucagon-like peptide-1 receptor (GLP1R) agonists in the treatment of type 2 diabetes (T2D) and obesity has stimulated intense interest in their pleiotropic effects beyond glycaemic con-trol and weight loss [4].”
Ahmed, M., Fatima, S., bin shafiq, S., Mansoor, K., Aqsa, F., Naveed, M. A., Ali, A., Sandhyavenu, H., Qureshi, B. G., & Neppala, S. (2026) · Canadian Respiratory Journal · doi:10.1155/carj/3655829
Histoire des incrétines GLP-1/GIP – De l’hormone au médicament couteau-suisse
Portha, B. (2026) · Biologie Aujourd hui · doi:10.1051/jbio/2026005
Acupuncture modulates migraine-related neural and neuroendocrine regulatory pathways
Huang, H., Tao, Y., Zhang, Y., Luo, F., Hu, H., Huang, Z., Lu, W., Sun, Y., Jin, X., Li, J., et al. (2026) · The Journal of Headache and Pain · doi:10.1186/s10194-026-02481-1
Biryukova, E. V., & Викторович, Ш. М. (2026) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2026-103
Current status of cardiovascular risk factor control: are we meeting the targets?
Burgos, L. M., Costabel, J. P., Cano, P. R., Micali, G., Koslowski, P. T., & Zamorano, J. L. (2026) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2026.103428
Beniwal-Patel, P. M., Samaan, S., Abreu, M. T., Deepak, P., & Yarur, A. J. (2026) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izag151 · Cited by 2
Beyond Weight Loss: Skeletal Muscle Health During Incretin-Based Therapy in Patients with Diabesity
Mollero, E. L. M., Dozzani, I., Biamonte, E., Bendotti, G., Marzullo, P., Aimaretti, G., & Gallo, M. (2026) · Nutrients · doi:10.3390/nu18162654 · Cited by 3
“The introduction of tirzepatide, a first-in-class GLP-1/GIP RA, has fundamentally reshaped the therapeutic landscape of obesity and T2DM [6,37,38].”
Zhong, X., Zhao, Y., Han, M., Zheng, Q., Cheng, Q., Shi, B., & Zhang, Y. (2026) · Hormone and Metabolic Research · doi:10.1055/a-2923-3830
Ming, Q., & Li, Z. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1914155
Jagasia, K., Pfeiffer, A. M., & Vitale, K. (2026) · Journal of Aging Research and Lifestyle · doi:10.1016/j.jarlif.2026.100083 · Cited by 2
“These effects led to their initial approval for the treatment of type 2 diabetes mellitus (T2DM) in 2005 [1,2].”
For Weight Loss: Why Do GLP-1 Agonists Work, and How Can We Make Them Work Better?
Giang, C., Meng, J., Mohammad, M. A., Liu, Z., Wu, X., & Zhu, Y. (2026) · Biology · doi:10.3390/biology15161395 · Cited by 1
“This remarkable efficacy, combined with approximately two decades of established safety [11], marks the first time a medication has approached the effectiveness of bariatric surgery for obese patients [12,13].”
He, W., Yi-di, S., Wang, X., He, S.-Y., Tao, X., Yuan, S.-X., Zhou, L., & Long, E.-W. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1889594
“People with obesity and T2DM generally have a poorer metabolic background and are, therefore, less likely to achieve the same degree of weight loss as those without T2DM (Losada-Díaz et al., 2024; Bays, 2023; Drucker, 2024).”
Exercise and physical activity interventions in type 2 diabetes mellitus
Su, W., Li, X., Gou, H., Yuan, L., Lin, L., Lin, X., Wang, X., Xiong, Y., & Luan, Y. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1887543
Montoye, A. H. K., Grosicki, G. J., Babcock, M. C., Fielding, F., von Hippel, W., Chapman, C. J., Henderson, D., Lee, V. H., & Holmes, K. E. (2026) · Journal of Sports Sciences · doi:10.1080/02640414.2026.2721858 · Cited by 1
Disease-modifying anti-diabetic drugs (DMADDs): bridging the SIMPLE approach to disease interception
Koca, N., Uyar, S., Şahintürk, Y., Yıldız, H., Prato, S. D., & DeFronzo, R. A. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-026-03346-2
“Analyses from the HARMONY [65] and SELECT [13] trials have reinforced this view by demonstrating cardiovascular protection with albiglutide and semaglutide that is not proportional to weight loss [66].”
Jargiło, M., Kucza, J., & Mrukwa–Kominek, E. (2026) · Ophthalmology · doi:10.5114/oku/226459
“The principal agents in this class include semagluti-de, liraglutide, and dulaglutide [31].”
Kavsara, H. K. (2026) · Journal of Medical Topics and Updates · doi:10.58651/jomtu.1980569
Effects of obesity on brain health and cognition
McEntee, C. M., Savelieff, M. G., Noureldein, M. H., Eid, S., Grisold, W., Hassenstab, J. J., & Feldman, E. L. (2026) · Nature Reviews Neurology · doi:10.1038/s41582-026-01251-6 · Cited by 2
“GLP-1RAs are now widely used to treat obesity 185 , and they might offer the same neurocognitive benefits in people with obesity-related cognitive impairment.”
Stump, K., Kelleher, S., Aynaszyan, S., Ricci, S., & Pazionis, T. J. C. (2026) · Clinical Spine Surgery A Spine Publication · doi:10.1097/bsd.0000000000002145
A new therapeutic era in childhood and adolescent obesity: opportunities and future challenges
Molina-Giraldo, P., Suárez-Ortega, L., & Ramon‐Krauel, M. (2026) · Anales de Pediatría (English Edition) · doi:10.1016/j.anpede.2026.504194
Adhikari, S., Carlyle, B. C., & de Wet, H. (2026) · The Journal of Precision Medicine Health and Disease · doi:10.1016/j.premed.2026.100057
Jastreboff, A. M., Ard, J. D., Hall, K. D., Kaplan, L. M., Krumholz, H. M., Name, M. A. V., Ryan, D. H., & Drucker, D. J. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnag025 · Cited by 1
“…surrounding the potential for GLP-1 RA based medicines to slow gastric emptying and increase the risk of retained gastric contents and aspiration have sparked multiple recommendations surrounding the optimal management of individuals requiring anesthesia and diagnostic or surgical procedures (183).”
InfluentialSelf-citationChirapongsathorn, S., & Tacke, F. (2026) · Digestion · doi:10.1159/dig/acmag014
Hu, J., Zhang, Y., Wang, M., Zhang, B., Zhang, B., Ke, C., Tang, C., Xia, J., Zhao, Q., Gao, H., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c00175
GIORGIO, C. M., Romanò, C., Arisi, M., Rossi, M., Venturini, M., Mezzana, S., Grigolato, L., Gallì, B., Nicoletti, M. M., Tomasi, C., et al. (2026) · Dermatology and Therapy · doi:10.1007/s13555-026-01916-6
“…inflammation; experimental evidence also suggests complementary effects of GIP receptor activation on adipose tissue remodeling and cytokine production, although the relative contribution of direct GIP signaling versus enhanced metabolic efficacy remains incompletely understood [1, 20, 21].”
The Dark Side of GLP-1 Receptor Agonists: Risks and Adverse Events
Nawal, C. L., Saini, H. L., Rankawat, G., & Chejara, R. S. (2026) · Journal of the Association of Physicians of India · doi:10.59556/japi.74.1655
Brucar, L. R., Miller, K. M., & Volkow, N. D. (2026) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2026.106990
“Glucagon-like peptide-1 receptor agonist-based pharmacotherapies (GLP-1RAs) are highly effective treatments for metabolic disorders like type II diabetes mellitus (T2DM) and obesity (Drucker, 2024).”
He, K., Wei, Y., Zhao, H., Zhang, L., Wu, F., Liu, R., Zhang, Y., Wang, Y., Chen, H., ZENG, M., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71218 · Cited by 1
Williams, A. L., & Blevins, J. E. (2026) · Current Diabetes Reports · doi:10.1007/s11892-026-01640-7
“%) is observed in non-diabetic individuals with over-weight or obesity [103].”
Clinical Decision-Making for Incretin-Based Therapy in Neurofibromatosis Type 1
Ayar, U. D., Akurati, S., Petridis, S. F., Mejia, H., Udayakumar, V., Punjabi, N., Bernal‐Mizrachi, E., & Varghese, R. T. (2026) · AACE Endocrinology and Diabetes · doi:10.1016/j.aed.2026.07.024
GLP-1 Based Therapies for Obesity in Older Adults: Current Evidence and Emerging Treatments
Pendrey, A., Sierra, J. A. R., Alvarez, F. A., Muñoz, Y. M. F., & Sevilla‐Martir, J. (2026) · Global Journal of Obesity Diabetes and Metabolic Syndrome · doi:10.17352/gjodms.000071
New Amylin-Based Agonists for the Treatment of Obesity and Type 2 Diabetes Mellitus
Panou, T., Gouveri, E., Popovic, D. S., & Παπάνας, Ν. (2026) · Diabetes Therapy · doi:10.1007/s13300-026-01921-0
Rapp, H., Marr, D., Modany, A., Bryk, A., CHRISTIAN, N., & Good, C. B. (2026) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2026.32.10.1167
Genetically Proxied GIP ‐ GIPR Pathway Perturbation and Fracture Risk
Cheng, W., Liu, W., Wei, J., Zeng, C., Lyu, H., & Zhao, S. S. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71378
Klusek, K., Batory, M., Jakubowski, J., Kraska, K., Krasucka, N., Zynkowska, A., Skrzyniarz, A. M., Kiełbus, M., Oziębło, J., & Kijowska, M. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(51).2026.6114
Elbatreek, M. H., Li, Z., Yu, X., Gehred, N., Gromova, T., Chen, J., Huerta, M., Muraoka, N., Jensen, M. B., Kartha, V. K., et al. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag732 · Cited by 4
Ramasinghe, C., & Xu, B. (2026) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2026.105166
Jiang, L., Chen, X., Qian, J., Fang, K., Dai, C., Chang, D., Jin, L., Huang, W., Wang, Y., Duan, X., et al. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71845
More than just adipose: the impact of GLP1RA on lean tissue
Julien, M., Jeromson, S., & Wright, D. C. (2026) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.90062.2026
Rampengan, D. D., Hogipranata, M. O., Iqhrammullah, M., Fahdhienie, F., Rampengan, N. H., Empitu, M., & Habiburrahman, M. (2026) · Obesity Medicine · doi:10.1016/j.obmed.2026.100751
Incretin-Based Polypharmacology and the Redefinition of Cardiometabolic Medicine
Kanoia, S. B., Tiwari, A., Rizvi, S. W. A., & Tiwari, A. (2026) · Journal of Pharmaceutical and Biopharmaceutical Research · doi:10.25082/jpbr.2026.01.004
“The earlier observational signal of lower dementia risk among users therefore did not survive randomization, a cautionary precedent for the addiction indications, where evidence of reduced alcohol and nicotine use remains largely observational (L4) [4].”
Zheng, Y. J., Au, H. C. T., Le, G. H., Wong, S., Teopiz, K. M., Kwan, A. T. H., Rosenblat, J. D., Mansur, R. B., Rhee, T. G., Lo, H. K. Y., et al. (2026) · Acta Neuropsychiatrica · doi:10.1017/neu.2026.10097
“Beyond its role in glucose homeostasis, GLP-1 is integral to metabolism and body weight regulation, with GLP-1 receptor (GLP-1R) activation improving glycaemic control, reducing body weight, and lowering blood pressure (Drucker, 2024).”
Antidiabetic drugs and its pharmacological profile target in human for type 2 diabetes mellitus
Guzmán, D. C., Brizuela, N. O., Peraza, A. V., Olguín, H. J., Herrera, M. O., Jiménez, F. T., del Angel, D. S., & García, E. H. (2026) · Discover Medicine · doi:10.1007/s44337-026-00659-9
Glucagon-like-peptide-1 receptor agonists
Zhong, Q., Kruse, C., Glanz, T., Berges, M., & Eri, J. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-44037-3.01015-0
Belalcazar, L. M., Gao, D., Modi, S., Meer, A., & Kuo, Y. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71448
Smarkusz-Zarzecka, J., Radziszewska, M., Gofron, K. K., & Ostrowska, L. (2026) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-026-10098-7 · Cited by 1
GLP-1 RECEPTOR AGONISTS AND THYROID DISEASE: FROM MECHANISM TO CLINICAL PRACTICE
Milewska, A., Bociąg, A., Kowalski, K., Marciniak, R., & Ptach, Ł. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.4(52).2026.6324
Metadata
- Authors
- Drucker, D. J.
- Affiliations
- Mount Sinai Hospital (CA)
- Corresponding author
- Drucker, Daniel J.
- ORCID
- Drucker, Daniel J.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2024-06-06
- Volume
- 47
- Issue
- 11
- Pages
- 1873-1888
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W4399395008
- Semantic Scholar
- 306e8b284bd34405b3e79c99c37f0dec0c95f1ed
- Cited by
- 383
- References
- 171
- Citations by year
- 2026: 176 · 2025: 168 · 2024: 39
- FWCI
- 22.48
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Canadian Institutes for Health Research (154321)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- GLP-1 receptor agonists, type 2 diabetes, obesity, tirzepatide, retatrutide, survodutide, cardiorenal benefits, drug safety, fracture, bone mineral density, muscle strength, gastrointestinal motility, anesthesia, pancreatic diseases, biliary tract diseases, cancer risk, cardiometabolic disease, personalized medicine
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Obesity, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.